Research output per year
Research output per year
Personal profile
Research interests
Experimental therapeutics and clinical trial development and management for NFI-related peripheral nervous system tumors.
Clinical interests
Pediatric oncology, pediatric solid tumors, with a particular interest in treating NFI-related peripheral nervous system tumors.
Fingerprint
Dive into the research topics where Amy Armstrong is active. These topic labels come from the works of this person and are generated automatically. Together they form a unique fingerprint. Contact the Profiles team with questions.
- 1 Similar Profiles
Collaborations and top research areas from the last five years
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
-
Associations of Patient Age, Tumor Nephrectomy Weight, and Tumor Diameter with Event-Free and Overall Survival in Stage I or II Favorable Histology Wilms Tumor: A Pooled Analysis of Children's Oncology Group Studies AREN0532 and AREN03B2
AREN03B2 Authorship Group, 2025, (Accepted/In press) In: Annals of surgery.Research output: Contribution to journal › Article › peer-review
1 Scopus citations -
Clinical and pathologic features of 535 patients with congenital mesoblastic nephroma: a report from the Children’s Oncology Group
AREN03B2 Authorship Group, 2025, (Accepted/In press) In: Annals of surgery. 10.1097/SLA.0000000000006862.Research output: Contribution to journal › Article › peer-review
-
Collaborative frontiers in pediatric neuro-oncology: establishing an international tumor board for enhanced care and global impact
Shatara, M., Brossier, N. M., Cluster, A., Mian, A. Y., Dahiya, S., Armstrong, A. E., Hirbe, A. C., Gutmann, D. H., Aldape, K. & Abdelbaki, M. S., Aug 2025, In: International Journal of Clinical Oncology. 30, 8, p. 1659-1669 11 p.Research output: Contribution to journal › Article › peer-review
-
Efficacy and safety of entrectinib in children with extracranial solid or central nervous system (CNS) tumours harbouring NTRK or ROS1 fusions
Desai, A. V., Bagchi, A., Armstrong, A. E., van Tilburg, C. M., Basu, E. M., Robinson, G. W., Wang, H., Casanova, M., André, N., Campbell-Hewson, Q., Wu, Y., Cardenas, A., Ci, B., Ryklansky, C., Devlin, C. E., Meneses-Lorente, G., Wulff, J., Hutchinson, K. E., Gajjar, A. & Fox, E., May 2 2025, In: European Journal of Cancer. 220, 115308.Research output: Contribution to journal › Article › peer-review
Open Access2 Scopus citations -
Mirdametinib, an FDA-Approved MEK1/2 inhibitor for adult and pediatric NF1-associated plexiform neurofibromas
Oztosun, G., Armstrong, A. & Hirbe, A. C., 2025, In: Expert Opinion on Investigational Drugs. 34, 9, p. 665-673 9 p.Research output: Contribution to journal › Review article › peer-review
Open Access